Cambridge Healthtech Institute’s Inaugural

Lead and Candidate Selection for Therapeutic Proteins  

Strategies and Best Practices for Key Early Decision Gates

September 16-17, 2020

 

The screenings and studies that comprise a company's lead and candidate selection funnel are an essential stage of biopharmaceutical R&D, and good selections not only ensure that the best quality molecules are chosen for advancement, but that these match target profiles for efficacy, safety and pharmacology. The Lead and Candidate Selection for Therapeutic Proteins conference presents a wide range of strategies, models and technologies used for these evaluations, and considers the best practices in this field. Case studies from both large and small organizations will showcase the innovative ways organizations have employed these tools to help ensure rapid progression through subsequent development steps and the prospects for success in the clinic.

Preliminary Agenda

ESSENTIAL LEAD SELECTION STUDIES

A Milligram-scale High-throughput Antibody Production and Analysis Workflow to Enable Multiparameter Lead Selection

Laird Bloom, PhD, Associate Director, Pfizer

Incorporating High-Throughput Developability Screening into Early Stage Drug Discovery Workflows

Christina Palmer, Scientist, Antibody Discovery, Biogen

SAFETY AND IMMUNOGENICITY EVALUATION

Preclinical Risk Assessment Tools to Support Probability of Immunogenicity Risk in the Clinic

Vibha Jawa, PhD, Director, Risk Assessment and Clinical Immunogenicity, Merck

Presentation to be Announced

DISCOVERY OF FUNCTIONAL ANTIBODIES

Automated High-Throughput Functional Screening in Antibody Discovery

John Blankenship, PhD, Senior Investigator and Group Leader, Antibody Discovery, Novartis

The Trianni Mouse®: An Exceptional Transgenic Mouse Platform for the Discovery of Human Therapeutic Antibodies

Linda Masat, PhD, Vice President, Business Development, TRIANNI, Inc.

Co-Discovery of Antibodies and Their Endogenous Protein Targets

Jason Lavinder, PhD, Chemical Engineering, University of Texas at Austin

CHALLENGES IN EARLY PREDICTIVE STUDIES

Advanced Assays for Microfluidic and Single Cell Screening

Karyn McFadden, PhD, Scientist, Amgen, Canada

Interfacing Computational Modeling and Biophysical Characterization to Guide Therapeutic Protein Engineering

Andrew Urick, PhD, Senior Scientist, AbbVie

Talk Title to be Announced

Jim Freeth, PhD, C-Managing Director, Retrogenix Ltd., United Kingdom

Early Stage Potency Assays

Marco Reis, PhD, Senior Scientist, Functional Characterization, Large Molecule Research, Roche, Germany




For more details on the conference, please contact:
Kent Simmons

Senior Conference Director

Cambridge Healthtech Institute

Phone: (+1) 207-869-9199
Email: ksimmons@healthtech.com

 

For partnering and sponsorship information, please contact:
Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286
Email: reymael@healthtech.com